Gewinnerbranchen der Jahre 2006 bis 2040 (Seite 682)
eröffnet am 10.12.06 16:57:17 von
neuester Beitrag 16.02.24 09:33:08 von
neuester Beitrag 16.02.24 09:33:08 von
Beiträge: 94.068
ID: 1.099.361
ID: 1.099.361
Aufrufe heute: 3
Gesamt: 3.536.429
Gesamt: 3.536.429
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| gestern 18:26 | 276 | |
| heute 01:57 | 162 | |
| heute 02:30 | 136 | |
| gestern 23:31 | 112 | |
| gestern 19:56 | 88 | |
| heute 00:43 | 81 | |
| gestern 18:52 | 77 | |
| gestern 23:40 | 71 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.497,94 | +0,01 | 177 | |||
| 2. | 2. | 178,08 | -0,40 | 71 | |||
| 3. | 14. | 5,5260 | -1,11 | 48 | |||
| 4. | 6. | 4,1500 | +0,24 | 43 | |||
| 5. | 9. | 0,6906 | +12,73 | 38 | |||
| 6. | 4. | 0,1925 | 0,00 | 32 | |||
| 7. | 30. | 0,3340 | +76,72 | 31 | |||
| 8. | 39. | 6,4260 | +1,39 | 30 |
Beitrag zu dieser Diskussion schreiben
Feedback
zu Idorsia.
Janssen submits European Marketing Authorization Application for ponesimod for treatment of 03/04/2020 | 01:00am EST
Marketing Authorization Application (MAA) based on data from the head-to-head OPTIMUM Phase 3 study, presented at the 35th Congress of The European Committee for Treatment and Research in Multiple Sclerosis
Idorsia Pharmaceuticals Ltd and Actelion Pharmaceuticals Ltd, a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, have a revenue-sharing agreement in respect to ponesimod
Allschwil, Switzerland – March 4, 2020
Idorsia Ltd (SIX: IDIA) today informed that the Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a MAA to the European Medicines Agency (EMA) seeking approval for ponesimod for the treatment of adult patients with relapsing multiple sclerosis (MS).
Janssen submits European Marketing Authorization Application for ponesimod for treatment of 03/04/2020 | 01:00am EST
Marketing Authorization Application (MAA) based on data from the head-to-head OPTIMUM Phase 3 study, presented at the 35th Congress of The European Committee for Treatment and Research in Multiple Sclerosis
Idorsia Pharmaceuticals Ltd and Actelion Pharmaceuticals Ltd, a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, have a revenue-sharing agreement in respect to ponesimod
Allschwil, Switzerland – March 4, 2020
Idorsia Ltd (SIX: IDIA) today informed that the Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a MAA to the European Medicines Agency (EMA) seeking approval for ponesimod for the treatment of adult patients with relapsing multiple sclerosis (MS).
Antwort auf Beitrag Nr.: 62.863.287 von clearasil am 03.03.20 12:15:27Krasser Fall. Aber Fakt ist, Corona-Schutzimpfungen wird es voraussichtlich ab 2022 weltweit geben und es wird ähnlich der Grippe-Schutzimpfung ein Markt entstehen, der groß ist und nicht mehr so schnell verschwinden sollte. Daher lohnen auch auf dem jetzigen Niveau die typischen Verdächtigen wie GSK.
Vlt. hat BMY bereits die Korrektur abgeschlossen, nachdem Bernie das moderate Demokratenlager "zwangsvereinigt" hat.
Vlt. hat BMY bereits die Korrektur abgeschlossen, nachdem Bernie das moderate Demokratenlager "zwangsvereinigt" hat.
corona und die auswüchse:
"But among the biggest examples of hype stands Novavax, a biotech that has burned through $1.5bn of investor cash with no marketed product to show for it, instead using press releases about the likes of Sars, RSV and bird flu as a prelude to cash calls. Yesterday it announced plans to develop a Covid-19 vaccine."
https://www.evaluate.com/vantage/articles/analysis/coronavir…
"But among the biggest examples of hype stands Novavax, a biotech that has burned through $1.5bn of investor cash with no marketed product to show for it, instead using press releases about the likes of Sars, RSV and bird flu as a prelude to cash calls. Yesterday it announced plans to develop a Covid-19 vaccine."
https://www.evaluate.com/vantage/articles/analysis/coronavir…
www.sueddeutsche.de/wirtschaft/jack-welch-tot-nachruf-1.4828…
Meine GE-Aktien habe ich verkauft, als Jack Welch dort noch CEO war.
Trading Spotlight
Heizöl for future 
Heute geprüft, wieviel Platz im Öltank ist. Der nächste Winter kommt bestimmt.
www.tecson.de/pheizoel.html * www.investing.com/indices/indices-futures
Morgen ist auch noch ein Tag und der Dollar fällt. Geht doch.
Heute geprüft, wieviel Platz im Öltank ist. Der nächste Winter kommt bestimmt.
www.tecson.de/pheizoel.html * www.investing.com/indices/indices-futures
Morgen ist auch noch ein Tag und der Dollar fällt. Geht doch.
zu SGMO.
https://www.marketscreener.com/BIOGEN-INC-4853/news/Biogen-a…
"CAMBRIDGE - Biogen Inc. (Nasdaq: BIIB) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer's disease, ST-502 for synucleinopathies including Parkinson's disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets.
The companies will leverage Sangamo's proprietary zinc finger protein (ZFP) technology delivered via adeno-associated virus (AAV) to modulate the expression of key genes involved in neurological diseases.
'As a pioneer in neuroscience, Biogen will collaborate with Sangamo on a new gene regulation therapy approach, working at the DNA level, with the potential to treat challenging neurological diseases of global significance. We aim to develop and advance these programs forward to investigational new drug applications,' said Alfred Sandrock Jr., M.D., Ph.D., Executive Vice President, Research and Development at Biogen."
"Upon closing of this transaction, Sangamo will receive $350 million comprised of $125 million in a license fee payment and $225 million from the sale of new Sangamo stock, or approximately 24 million shares at $9.21 per share. In addition, Sangamo may receive up to $2.37 billion in other development, regulatory, and commercial milestone payments, including up to $925 million in pre-approval milestone payments and up to $1,445 million in first commercial sale and other sales-based milestone payments. Sangamo will also be eligible to receive from Biogen tiered high single digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration."
hier is noch nix passiert, ausser Hüpfer an einem sehr schlechten Tag:
https://www.marketscreener.com/BIOGEN-INC-4853/news/Biogen-a…
"CAMBRIDGE - Biogen Inc. (Nasdaq: BIIB) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer's disease, ST-502 for synucleinopathies including Parkinson's disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets.
The companies will leverage Sangamo's proprietary zinc finger protein (ZFP) technology delivered via adeno-associated virus (AAV) to modulate the expression of key genes involved in neurological diseases.
'As a pioneer in neuroscience, Biogen will collaborate with Sangamo on a new gene regulation therapy approach, working at the DNA level, with the potential to treat challenging neurological diseases of global significance. We aim to develop and advance these programs forward to investigational new drug applications,' said Alfred Sandrock Jr., M.D., Ph.D., Executive Vice President, Research and Development at Biogen."
"Upon closing of this transaction, Sangamo will receive $350 million comprised of $125 million in a license fee payment and $225 million from the sale of new Sangamo stock, or approximately 24 million shares at $9.21 per share. In addition, Sangamo may receive up to $2.37 billion in other development, regulatory, and commercial milestone payments, including up to $925 million in pre-approval milestone payments and up to $1,445 million in first commercial sale and other sales-based milestone payments. Sangamo will also be eligible to receive from Biogen tiered high single digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration."
hier is noch nix passiert, ausser Hüpfer an einem sehr schlechten Tag:
mal zu wirklichem Biosalat. 
is auch nich so der bringer ... aldi and lidl take it all.
Meanwhile, Whole Foods Market has cut prices on hundreds of items including organic produce since Amazon.com Inc. acquired the company three years ago.
As a result, specialty grocers are having a hard time convincing customers to pay a premium to shop in their stores. And without the revenue and reach of bigger chains, they have also been hesitant to match price cuts or to invest in new services like delivery.
Regional chains Earth Fare, Lucky's Market and Fairway Market have filed for bankruptcy in recent weeks. Shares in Sprouts Farmers Market Inc. and Natural Grocers by Vitamin Cottage Inc. are down respectively about 30% and nearly 50% over the past year.
"Differentiation can be ephemeral. Retail is an open book of copycats," said Scott Moses, managing director at investment bank PJ Solomon who is advising Lucky's and Fairway.
https://www.marketscreener.com/NATURAL-GROCERS-BY-VITAMI-110…
is auch nich so der bringer ... aldi and lidl take it all. Meanwhile, Whole Foods Market has cut prices on hundreds of items including organic produce since Amazon.com Inc. acquired the company three years ago.
As a result, specialty grocers are having a hard time convincing customers to pay a premium to shop in their stores. And without the revenue and reach of bigger chains, they have also been hesitant to match price cuts or to invest in new services like delivery.
Regional chains Earth Fare, Lucky's Market and Fairway Market have filed for bankruptcy in recent weeks. Shares in Sprouts Farmers Market Inc. and Natural Grocers by Vitamin Cottage Inc. are down respectively about 30% and nearly 50% over the past year.
"Differentiation can be ephemeral. Retail is an open book of copycats," said Scott Moses, managing director at investment bank PJ Solomon who is advising Lucky's and Fairway.
https://www.marketscreener.com/NATURAL-GROCERS-BY-VITAMI-110…
Antwort auf Beitrag Nr.: 62.839.070 von HenryScheinulf am 29.02.20 23:18:36
sehr guter Link - in diesen Tagen am besten dreimal täglich lesen.
Perfekt.
Zitat von HenryScheinulf: Guten Morgan.
www.fool.com/investing/general/2014/10/16/some-things-to-rem…
sehr guter Link - in diesen Tagen am besten dreimal täglich lesen.
Perfekt.
Antwort auf Beitrag Nr.: 62.833.238 von umbre am 28.02.20 23:50:12
wg. Softwarefehler 29.2. Mißverständnis im Getränkeabholmarkt
.
.
Nach den letzten 3 wird allerdings noch gefahndet.
(Kern der Terrorzelle "no Tierversuche in der Pharmaindustrie")
Guten Morgan.
www.fool.com/investing/general/2014/10/16/some-things-to-rem…
Zitat von umbre: Besser kann man auf die
aktuelle Hysterie nicht antworten
wg. Softwarefehler 29.2. Mißverständnis im Getränkeabholmarkt
.
.
Nach den letzten 3 wird allerdings noch gefahndet.
(Kern der Terrorzelle "no Tierversuche in der Pharmaindustrie")
Guten Morgan.
www.fool.com/investing/general/2014/10/16/some-things-to-rem…
Durchsuchen
